Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

245070

Sigma-Aldrich

Tetramethylammonium acetate

≥97%

Synonym(s):

N,N,N-trimethyl-methanaminium acetate

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Linear Formula:
(CH3)4N(OCOCH3)
CAS Number:
10581-12-1
Molecular Weight:
133.19
Beilstein:
3571830
EC Number:
234-179-3
MDL number:
MFCD00011630
UNSPSC Code:
12352116
PubChem Substance ID:
24854730
NACRES:
NA.22

Quality Level

200

Assay

≥97%

form

solid

mp

184 °C (dec.) (lit.)

SMILES string

CC([O-])=O.C[N+](C)(C)C

InChI

1S/C4H12N.C2H4O2/c1-5(2,3)4;1-2(3)4/h1-4H3;1H3,(H,3,4)/q+1;/p-1

InChI key

MRYQZMHVZZSQRT-UHFFFAOYSA-M

Looking for similar products? Visit Product Comparison Guide

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
U8259
U2072
U9050
U7852
MKCF1193

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniel L J Thorek et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(2), 881-891 (2018-09-27)
The impact of androgen receptor (AR) activity in breast cancer biology is unclear. We characterized and tested a novel therapy to an AR-governed target in breast cancer.Experimental Design: We evaluated the expression of prototypical AR gene products human kallikrein 2
Aleksandra M Urbanska et al.
Cancer biotherapy & radiopharmaceuticals, 35(6), 459-473 (2020-02-06)
An α particle-emitting nanodrug that is a potent and specific antitumor agent and also prompts significant remodeling of local immunity in the tumor microenvironment (TME) has been developed and may impact the treatment of melanoma. Biocompatible ultrasmall fluorescent core-shell silica
Alexey A Nazarov et al.
Dalton transactions (Cambridge, England : 2003), 44(8), 3614-3623 (2014-11-20)
Chemotherapeutics for the treatment of tumorigenic conditions that feature novel modes of action are highly sought after to overcome the limitations of current chemotherapies. Herein, we report the conjugation of the alkylating agent chlorambucil to the RAPTA scaffold, a well-established

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service